Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT06404112

RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)

Conditions: Long COVID, Long COVID-19, Sleep Disturbance

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 470
Sponsor: Duke University

Location: All sites listed under NCT06404086 Durham North Carolina

Summary

The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospective, multi-center, multi-arm, randomized controlled platform trial evaluating potential interventions for PASC-mediated sleep disturbances. The hypothesis is that symptoms of sleep and circadian disorders that emerge in patients with PASC can be improved by phenotype-targeted interventions. Specific sleep and circadian disorders addressed in this protocol include sleep-related daytime impairment (referred to as hypersomnia) and complex PASC-related sleep disturbance (reflecting symptoms of insomnia and sleep-wake rhythm disturbance).

Eligibility Criteria

Inclusion Criteria: • See NCT06404086 for RECOVER-SLEEP: Platform Protocol level inclusion criteria which applies to this appendix Exclusion Criteria: • See NCT06404086 for RECOVER-SLEEP: Platform Protocol level exclusion criteria which applies to this appendix Additional Appendix B (CPSD) Level Inclusion Criteria: The following additional exclusion criteria are to be considered together for determining eligibility. They are separated here by TL and melatonin only for presentation. RESET-PASC presents no additional exclusions. TAILORED LIGHTING EXCLUSION CRITERIA 1. Severe visual impairments affecting sensitivity or ability to respond to light 2. Severe photosensitivity dermatitis 3. Severe progressive retinal disease, eg, macular degeneration 4. Permanently dilated pupil, eg, following certain cataract surgeries 5. Unwilling to remove or not wear blue-light-blocking glasses during TL dosing MELATONIN EXCLUSION CRITERIA 1\. Sleep medication, if not willing to washout for 4 weeks.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06404112). StuddyBuddy aggregates publicly available trial information.